News & Events
News Releases
August 8, 2008
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
January 5, 2010
Icon Bioscience Initiates Phase 2/3 Pivotal Clinical Study of Novel Ophthalmic Drug Candidate
May 4, 2010
Icon to Present Clinical Data on Verisome Technology in Cystoid Macular Edema at the ARVO Annual Meeting
December 7, 2011
Icon Appoints Murahashi Vice President, Clinical Development
January 3, 2013
Icon’s Melphalan Intraocular Injection Granted U.S. Orphan Drug Designation For the Treatment of Retinoblastoma